Hims buys at-home testing company Trybe Labsnews2025-02-19T21:24:53+00:00February 19th, 2025|Endpoints News|
Epitopea secures R&D deal with Merck for tumor-specific antigensnews2025-02-19T12:00:37+00:00February 19th, 2025|Endpoints News|
Arcus touts early kidney cancer data as Gilead declines optionnews2025-02-18T16:34:12+00:00February 18th, 2025|Endpoints News|
After research pivot, Biogen beefs up pipeline with Stoke’s late-stage Dravet candidatenews2025-02-18T15:05:05+00:00February 18th, 2025|Endpoints News|
How Bain’s $3.3B deal for a centuries-old Japanese pharma came to fruitionnews2025-02-14T15:28:33+00:00February 14th, 2025|Endpoints News|
Idorsia’s Tryvio licensing negotiations collapse amid cash squeezenews2025-02-13T15:37:05+00:00February 13th, 2025|Endpoints News|
Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage testnews2025-02-13T11:47:59+00:00February 13th, 2025|Endpoints News|
Roche sends experimental CNS drugs to Newleos, a new biotech backed with $93.5Mnews2025-02-13T05:00:31+00:00February 13th, 2025|Endpoints News|
Biogen gets $250M in Royalty Pharma deal for lupus programnews2025-02-12T11:45:46+00:00February 12th, 2025|Endpoints News|
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthosnews2025-02-11T12:21:43+00:00February 11th, 2025|Endpoints News|
